Salix Ulcerative Colitis Drug Shows Positive Results in Study
Posted on: Tuesday, 9 October 2007, 06:00 CDT
Pharmaceutical company Salix has reported the succesful completion of the second of two Phase III registration trials to evaluate the safety and efficacy of granulated mesalamine, which is under development for the maintenance of remission in patients with ulcerative colitis.
Results from the study indicate that a statistically significantly greater proportion of subjects dosed once-a-day with 1.5 grams of granulated mesalamine remained relapse-free over six months of treatment than patients dosed with placebo.
Bill Forbes, vice president of R&D at Salix Pharmaceuticals, said: "The outcome of this second, 300-subject, multicenter, six-month, double-blind, randomized, placebo-controlled study confirms the results of the study reported in September 2007.
"The results of this second study again demonstrate the utility of our novel delayed and extended release formulation of mesalamine, dosed once a day in this study, to successfully maintain remission in ulcerative colitis patients. They will continue to anticipate a December 2007 NDA submission for this product."
Salix acquired rights to market granulated mesalamine in the US from Dr. Falk Pharma of Freiburg, Germany.
Source: Datamonitor
Related Articles
- Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
- Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
- Athersys Initiates Patient Dosing in Phase I Acute Myocardial Infarction Study
- Data Released Today Demonstrate That Mesalamine Granules Maintain Remission in Ulcerative Colitis Patients Who Switch From Another 5-ASA
- Chelsea Therapeutics Begins Patient Dosing in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
- MannKind Corporation Announces Positive Results From a Phase 2b Dose-Ranging Study of Technosphere(R) Insulin in Patients With Type 2 Diabetes
- Medivation Announces First Patient Dosed in Phase II Trial With Dimebon for Treating Alzheimer's Disease
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Adults With Primary Sleep Maintenance Insomnia
- FibroGen Reports Phase 1 Results of Investigational Oral Anemia Therapy, FG-2216, and New Data From Phase 2A Study in Anemic Chronic Kidney Disease Patients
 |
 |
User Comments (0)
RSS Feeds